Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer

Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qiang, Chen, Dong-Sheng, Liu, Yuan-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/
https://www.ncbi.nlm.nih.gov/pubmed/35359396
http://dx.doi.org/10.3389/fonc.2022.853211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/
https://www.ncbi.nlm.nih.gov/pubmed/35359396
http://dx.doi.org/10.3389/fonc.2022.853211

Ejemplares similares